Newsroom

CRESEMBA™ now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis

Blainville, Québec, May 2nd, 2019 – AVIR Pharma Inc. (AVIR), is pleased to announce that CresembaTM (isavuconazole, as isavuconazonium sulfate), an antifungal approved for the treatment of adult patients with invasive aspergillosis or with invasive mucormycosis, is now available in Canada.1 Invasive aspergillosis and invasive mucormycosis are life-threatening fungal infections often occurring in patients with solid organ transplants, cancer and other immunocompromised patients.

Read More

Avir Pharma announces the availability of ZEVTERA™ (ceftobiprole medocaril) in Canada

Blainville, Québec, April 10, 2018 – AVIR Pharma Inc. (AVIR), a Canadian specialty pharmaceutical company, an affiliate of the Laboratoire RIVA Group, announced today that the hospital antibiotic ZEVTERA™ (ceftobiprole medocaril) is now available in Canada. ZEVTERA™ is approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP), excluding ventilator- associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP).

Read More

Avir Pharma announces distribution agreement with Basilea Pharmaceutica for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada

Blainville, Québec, June 14, 2017 – Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, announced today that it has entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. (SIX: BSLN) for its antifungal Cresemba® (isavuconazole) and antibiotic Zevtera® (ceftobiprole).

Read More

Events we attend

We are always interested in meeting and working with potential new partners that are interested in collaborating with us. We participate in numerous partnering conferences across the globe. Please let us know if you will be attending these events as we would welcome the opportunity to speak with you personally about potential opportunities for collaboration.